Last reviewed · How we verify
Chlonixin — Competitive Intelligence Brief
phase 2
clonixin
Dihydroorotate dehydrogenase (quinone), mitochondrial
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Chlonixin (CLONIXIN). Chlonixin works by inhibiting the enzyme dihydroorotate dehydrogenase, which is involved in the production of pyrimidine nucleotides.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chlonixin TARGET | CLONIXIN | phase 2 | clonixin | Dihydroorotate dehydrogenase (quinone), mitochondrial |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (clonixin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chlonixin CI watch — RSS
- Chlonixin CI watch — Atom
- Chlonixin CI watch — JSON
- Chlonixin alone — RSS
- Whole clonixin class — RSS
Cite this brief
Drug Landscape (2026). Chlonixin — Competitive Intelligence Brief. https://druglandscape.com/ci/clonixin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing